Hepatoma arterial-embolization prognostic (HAP) score, which consists of four tumor-related variables (alpha-fetoprotein [AFP] level and tumor size) and liver function-related variables (serum albumin and total bilirubin levels), has been proposed for predicting outcomes after TACE [13]. The gene discussed is AFP; the disease is hepatocellular carcinoma.